In the era of immune checkpoint inhibitors, pulmonary and critical care physicians frequently encounter patients taking these medications, usually after being admitted to the intensive care unit with life-threatening complications. These complications are rare, present with nonspecific and vague symptoms, which may delay the treatment and have high mortality. We report a very rare complication, with only two previously reported cases of a severe and potentially fatal side effect associated with anti-programmed cell death protein 1 (PD-1) immunotherapy with nivolumab. We provide a literature review to increase physicians' awareness about this rare side effect and suggest some recommendations derived from our experience.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687417 | PMC |
| http://dx.doi.org/10.7759/cureus.4869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical features, treatment, and outcomes of nivolumab induced psoriasis.
Invest New Drugs
December 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, Hunan, 410013, China.
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadequately defined. This study aims to investigate the clinical features and patterns of nivolumab-induced psoriasis, providing insights for the identification and management of this condition. Case reports and case series of nivolumab related psoriasis were gathered by searching Chinese and English databases for retrospective analysis until June 30, 2024.
View Article and Find Full Text PDFClinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia.
Invest New Drugs
October 2024
College of pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
Immune thrombocytopenia (ITP) represents an uncommon hematological side effect associated with nivolumab, and its distinct clinical attributes remain poorly defined. This research aimed to explore the clinical manifestations and outcomes of ITP induced by nivolumab. Reports on nivolumab induced ITP up to April 30, 2024, were collected for retrospective analysis.
View Article and Find Full Text PDFClinical features, treatment, and outcome of nivolumab-induced cholangitis.
Immunopharmacol Immunotoxicol
December 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Article Synopsis
- Cholangitis, a rare and severe reaction to the cancer drug nivolumab, has unclear symptoms; this study aimed to examine its clinical features, imaging results, and treatment options.
- The analysis included 38 patients, revealing that symptoms like abdominal pain and fever often appeared after an average of seven treatment cycles, with significant liver enzyme elevations noted in some cases.
- The study suggests clinicians should closely monitor for cholangitis in patients on nivolumab, use appropriate imaging techniques, and consider combining steroids with ursodeoxycholic acid (UDCA) for better treatment outcomes.
Clinical Features, Treatment, and Outcomes of Nivolumab-Induced Hemophagocytic Lymphohistiocytosis.
J Immunother
August 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haemophagocytic lymphohistiocytosis (HLH) is a rare and fatal immune-related event of nivolumab. The clinical features of nivolumab-induced HLH are unclear. The aim of this study was to investigate the clinical features, treatment, and outcome of nivolumab-induced HLH to provide information for prevention and treatment.
View Article and Find Full Text PDFClinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis.
Invest New Drugs
February 2024
Department of Pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, 410013, China.
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induced gastritis remain unclear. To explore the clinical characteristics of nivolumab induced gastritis, and to provide reference for the classification and treatment guidelines of immune checkpoint inhibitors -related gastritis. Case reports, case series, and clinical studies of nivolumab induced gastritis were retrospectively analyzed by searching the database from the establishment of the database until September 30, 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!